醫(yī)學(xué)詞匯縮寫(xiě)

Abbreviationor DefinitionspecialtermAE AdverseEventALT AlanineaminotransferaseAPTT ActivatedpartialthromboplastintimeAST AspartateaminotransferaseBUN BloodureanitrogenCK CreatinekinaseCR CompleteresponseCRF CaseReportFormCTONG ChineseThoracicOncologyGroupDCR DiseasecontrolrateDSMB DatasafetymonitoringboardEC EthicsCommitteeECG ElectrocardiogramECOG EasternCooperativeOncologyGroupeCRF ElectronicCaseReportFormEDC ElectronicDataCaptureEGF EpidermalgrowthfactorEGFR EpidermalgrowthfactorreceptorESF EligibilityScreeningFormGACT GuangdongAssociationofClinicalTrialsGCP GoodClinicalPracticeGMP GoodManufacturingPracticeGLP GoodLaboratoryPracticeHER1 Humanepidermalgrowthfactorreceptor1ICF InformedConsentFormICH InternationalConferenceonHarmonisationIB Investigator ’sBrochureIMP InvestigationalMedicinalProductIRC IndependentreviewcommitteeITT Intent-to-Treat

中文不良事件丙氨酸氨基轉(zhuǎn)移酶活化部分凝血活酶時(shí)間（反映內(nèi)源性凝血是否正常正常為 35~45s）天冬氨酸氨基轉(zhuǎn)移酶血尿素氮（檢查排尿功能是否異常）肌酸激酶（與細(xì)胞內(nèi)能量運(yùn)轉(zhuǎn)、肌肉收縮、ATP再生有直接關(guān)系的重要激酶，其升高反完全緩解病例報(bào)告表中國(guó)胸椎癌癥組織疾病控制率（DCR=CR+PR+SD）數(shù)據(jù)安全監(jiān)控委員會(huì)倫理委員會(huì)心電圖東方合作癌癥組織電子病例報(bào)告表電子數(shù)據(jù)采集表皮生長(zhǎng)因子表皮生長(zhǎng)因子受體篩查表廣東臨床實(shí)驗(yàn)協(xié)會(huì)藥品臨床試驗(yàn)質(zhì)量管理規(guī)范藥品生產(chǎn)質(zhì)量管理規(guī)范藥品非臨床研究質(zhì)量管理規(guī)范人表皮生長(zhǎng)因子受體 1知情同意書(shū)國(guó)際協(xié)調(diào)會(huì)議（由歐盟、美國(guó)、日本于1990年發(fā)起，對(duì)三方成員國(guó)家的人用藥品注冊(cè)要求的現(xiàn)存差異進(jìn)行協(xié)調(diào)的國(guó)際組織）研究者手冊(cè)研究型醫(yī)療產(chǎn)品（試驗(yàn)用藥品）獨(dú)立審查委員會(huì)意向性治療（參與隨機(jī)分組的對(duì)象，無(wú)論其是否接受改組的治療，最終都納入所分配的組中進(jìn)行療效的統(tǒng)計(jì)分析，這樣能保證不同組之間的可比性，防止由于效果不好而失仿的病人帶來(lái)的偏倚）MedDRAMRINCICTCAE

MedicalDictionaryforRegulatory國(guó)際醫(yī)學(xué)用語(yǔ)詞典ActivitiesMagneticresonanceimage磁共振成像NationalCancerInstituteCommonToxicity美國(guó)國(guó)家癌癥研究所常見(jiàn)毒性反應(yīng)標(biāo)準(zhǔn)CriteriaforAdverseEvents精品文檔交流AbbreviationorDefinitionspecialtermNSCLCNon-smallcelllungcancerORRObjectiveresponserateOSOverallsurvivalPDProgressivediseasePFSProgression-freesurvivalPSPerformanceStatusPPPerprotocolPRPartialresponsePROPatientreportedoutcomesRECISTResponseEvaluationCriteriainSolidTumorsPRLSReversibleposteriorleukencephalopathysyndromeSAESeriousAdverseEventSAPStatisticalAnalysisPlanTKITyrosinekinaseinhibitorULNUpperlimitofnormalVEGFVascularendothelialgrowthfactorBABETK毒物代謝動(dòng)力學(xué)HDACADME吸收、分布、代謝和消除HDACiAUC曲線下面積HPβCDBL伯基特淋巴瘤IC50Cmax最大藥物濃度ICHPC漿細(xì)胞瘤ipPK藥物代謝動(dòng)力學(xué)ivpo口服LD50RP2D臨床II期推薦劑量MTDsc皮下NEDCFDA國(guó)家食品藥品監(jiān)督管理局NMEFIH首次人用PBMC

中文非小細(xì)胞肺癌主觀反應(yīng)率總體存活率疾病進(jìn)展無(wú)進(jìn)展生存期體能狀況符合方案部分反應(yīng)患者自評(píng)結(jié)果實(shí)體瘤反應(yīng)評(píng)價(jià)標(biāo)準(zhǔn)可逆性后部白質(zhì)腦病綜合征、可逆性腦白質(zhì)后部綜合征posteriorreversibleencephalopathicsyndrome(PRES ）嚴(yán)重不良事件統(tǒng)計(jì)分析計(jì)劃酪氨酸激酶抑制劑正常上限血管內(nèi)皮生長(zhǎng)子生物利用度生物等效性組蛋白去乙?；附M蛋白去乙?；敢种苿┝u丙基倍